NASDAQ:RDEA - Ardea Biosciences Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started Previous CloseN/AToday's RangeN/A52-Week RangeN/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A Company ProfileChartEarnings HistoryFinancialsHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Ardea Biosciences, Inc. (Ardea) is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases. The Company's product portfolio includes Lesinurad (RDEA594), RDEA3170 and BAY 86-9766 (RDEA119). Lesinurad (RDEA594) is an inhibitor of the URAT1 kidney transporter for the treatment of gout. RDEA3170 is a URAT1 kidney transporter inhibitors for the treatment of gout. BAY 86-9766 (RDEA119) is a MEK inhibitor for the treatment of cancer. On June 19, 2012, AstraZeneca PLC acquired the Company. Receive RDEA News and Ratings via Email Sign-up to receive the latest news and ratings for RDEA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorN/A SymbolNASDAQ:RDEA CUSIPN/A Webwww.ardeabio.com Phone+1-858-6526500 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous EmployeesN/A Outstanding SharesN/AMarket Cap$0.00 Ardea Biosciences (NASDAQ:RDEA) Frequently Asked Questions What is Ardea Biosciences' stock symbol? Ardea Biosciences trades on the NASDAQ under the ticker symbol "RDEA." Has Ardea Biosciences been receiving favorable news coverage? News stories about RDEA stock have trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ardea Biosciences earned a coverage optimism score of 0.14 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 47.31 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days. View Recent Headlines for Ardea Biosciences. How do I buy shares of Ardea Biosciences? Shares of RDEA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. How can I contact Ardea Biosciences? Ardea Biosciences' mailing address is 4939 Directors Pl, SAN DIEGO, CA 92121-3829, United States. The biotechnology company can be reached via phone at +1-858-6526500. MarketBeat Community Rating for Ardea Biosciences (NASDAQ RDEA)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 78 (Vote Outperform)Underperform Votes: 61 (Vote Underperform)Total Votes: 139MarketBeat's community ratings are surveys of what our community members think about Ardea Biosciences and other stocks. Vote "Outperform" if you believe RDEA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDEA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/21/2018 by MarketBeat.com StaffFeatured Article: What are the Different Types of Leveraged Buyouts?